Nike Inc. Cl B (NKE) Financials Nov 14, 2014, 7:19
Nike Inc. Cl B (NKE) Financials Nov 14, 2014, 7:19 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Nike Inc. Cl B
Fiscal year is June-May. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 18.96B 20.89B 24.12B 25.33B 27.79B
Cost of Goods Sold (COGS) incl. D&A 10.61B 11.47B 13.62B 14.41B 15.34B
COGS excluding D&A 10.27B 11.12B 13.23B 13.95B 14.82B
Depreciation & Amortization Expense 337.2M 351M 395M 452M 518M
Depreciation 323.7M 335M 373M 438M 518M
Amortization of Intangibles 13.5M 16M 22M 14M 0
Gross Income 8.35B 9.42B 10.5B 10.93B 12.44B
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 5.99B 6.68B 7.41B 7.77B 8.77B
Research & Development - - - - -
Other SG&A 5.99B 6.68B 7.41B 7.77B 8.77B
Other Operating Expense 0 0 0 0 0
Unusual Expense (79.6M) (84M) (17M) (148M) 61M
EBIT after Unusual Expense 79.6M 84M 17M 148M (61M)
Non Operating Income/Expense 89.4M 29M (119M) (32M) (35M)
Non-Operating Interest Income 22.7M 24M 30M 26M 5M
Equity in Affiliates (Pretax) - - - 0 -
Interest Expense 36.4M 34M 39M 28M 43M
Gross Interest Expense 36.4M 34M 39M 28M 43M
Interest Capitalized 0 0 - - -
Pretax Income 2.52B 2.84B 2.98B 3.27B 3.54B
Income Tax 610.2M 711M 760M 808M 851M
Income Tax - Current Domestic 250.2M 346M 325M 503M 464M
Income Tax - Current Foreign 348.5M 441M 495M 398M 398M
Income Tax - Deferred Domestic 16.6M (61M) (50M) (3M) 5M
Income Tax - Deferred Foreign (5.1M) (15M) (10M) (90M) (16M)
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 1.91B 2.13B 2.22B 2.46B 2.69B
Minority Interest Expense 0 0 0 0 0
Net Income 1.91B 2.13B 2.22B 2.46B 2.69B
Extraordinaries & Discontinued Operations 0 0 0 21M 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 231M 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 (210M) 0
Net Income After Extraordinaries 1.91B 2.13B 2.22B 2.49B 2.69B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 1.91B 2.13B 2.22B 2.46B 2.69B
EPS (Basic) 1.97 2.24 2.42 2.51 3.05
Basic Shares Outstanding 971M 951M 920M 897.3M 883.4M
EPS (Diluted) 1.93 2.20 2.37 2.46 2.97
Diluted Shares Outstanding 987.8M 971.4M 939.6M 916.4M 905.8M
EBITDA 2.7B 3.09B 3.49B 3.61B 4.2B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...
Continue Reading
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue Reading
Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...
Continue Reading
Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...
Continue Reading
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Top 5 Most Recently Viewed Articles
Storm Properties Welcomes Bryan Leon as New Hire Storm Properties Inc., recognized as a significant player in the development, ownership, and management of a variety of properties, is delighted to announce the addition of Bryan Leon to their team as Land Acquisitions Manager. This appointment comes as part of the company's ongoing strategy to strengthen its position in...
Continue Reading
Revolutionizing Trade Setups with Innovative Scanner Technology Stock Market Guides is thrilled to introduce significant advancements to its cutting-edge stock scanner technology. The latest update empowers users by showcasing the historical track record of various trade setups it identifies, offering unparalleled insight to traders looking to enhance their market...
Continue Reading
EQT Life Sciences Champions $39 Million Investment in Aerska Advancing RNA Therapeutics EQT Life Sciences has recently announced a significant milestone: leading a $39 million Series A financing round in Aerska. This funding will be instrumental in pushing forward Aerska’s innovative brain shuttle technology. Designed to optimize the delivery of RNA interference...
Continue Reading
Understanding NVIDIA's Upcoming Earnings Announcement NVIDIA (NASDAQ: NVDA) is set to release its much-anticipated quarterly earnings report soon. Investors are keen to understand how the company is performing and what guidance it will provide for future quarters. Analysts predict that NVIDIA will announce an earnings per share (EPS) of $0.98, which indicates the level of...
Continue Reading
Innovative Partnership Forged for Enhanced Vehicle Safety NOVOSENSE Microelectronics, a key player in the semiconductor industry known for its high-performance analog and mixed-signal chips, is joining hands with Continental Automotive Technologies to enhance vehicle safety systems. This collaboration aims to push the envelope in developing automotive-grade sensors that...
Continue Reading